Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to Curis (CRIS – Research Report) today and set a price target of $26.00. The company’s shares closed last Friday at $15.72.
According to TipRanks, Devarakonda is a 4-star analyst with an average return of 16.2% and a 52.50% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Incyte, and Keros Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Curis with a $26.33 average price target, which is a 67.49% upside from current levels. In a report released on May 8, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.
CRIS market cap is currently $92.66M and has a P/E ratio of -1.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Curis (CRIS) Company Description:
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Read More on CRIS:
